Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575982 | 0.91 | TSHR (0.71) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL15677556 | 0.85 | TSHR (0.68) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL6361222 | 0.81 | TSHR (0.68) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL30259914 | 0.81 | TSHR (0.68) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL4588276 | 0.81 | MEN1 (0.81) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL5724113 | 0.81 | TSHR (0.72) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL12944908 | 0.81 | TSHR (0.62) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL12655254 | 0.80 | TSHR (0.57) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL11653865 | 0.80 | TSHR (0.61) | TSHRSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL11305715 | 0.79 | TSHR (0.69) | TSHRSMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | TSHR 1243/4885SMN1; SMN2 1093/4885HPGD 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.